Importer of Controlled Substances; Notice of Application, 19594-19595 [E9-9782]
Download as PDF
<![CDATA[
pwalker on PROD1PC71 with NOTICES
19594
Federal Register / Vol. 74, No. 81 / Wednesday, April 29, 2009 / Notices
presentations should attend a
prehearing conference to be held at 9:30
a.m. on May 28, 2009 at the U.S.
International Trade Commission
Building. Oral testimony and written
materials to be submitted at the hearing
are governed by sections 201.6(b)(2) and
201.13(f) of the Commission’s rules.
Written submissions.—Each party is
encouraged to submit a prehearing brief
to the Commission. The deadline for
filing prehearing briefs is May 28, 2009.
Parties may also file posthearing briefs.
The deadline for filing posthearing
briefs is June 8, 2009. In addition, any
person who has not entered an
appearance as a party to the
investigation may submit a written
statement of information pertinent to
the consideration of market disruption
or threat thereof and/or remedy on or
before June 8, 2009. Parties may submit
final comments on market disruption on
or before June 16, 2009 and on remedy
on or before June 24, 2009. Final
comments shall contain no more than
ten (10) double-spaced and single-sided
pages of textual material. All written
submissions must conform with the
provisions of section 201.8 of the
Commission’s rules; any submissions
that contain confidential business
information must also conform with the
requirements of section 201.6 of the
Commission’s rules. The Commission’s
rules authorize filing submissions with
the Secretary by facsimile or electronic
means only to the extent permitted by
section 201.8 of the rules (see Handbook
for Electronic Filing Procedures, https://
www.usitc.gov/secretary/
fed_reg_notices/rules/documents/
handbook_on_electronic_filing.pdf).
Persons with questions regarding
electronic filing should contact the
Secretary (202–205–2000).
In accordance with section 201.16(c)
of the Commission’s rules, each
document filed by a party to the
investigation must be served on all other
parties to the investigation (as identified
by the service list), and a certificate of
service must be timely filed. The
Secretary will not accept a document for
filing without a certificate of service.
Remedy.—No separate hearing on the
issue of remedy will be held. Those
parties wishing to present arguments on
the issue of remedy may do so orally at
the hearing or in their prehearing or
posthearing briefs or other written
submissions.
Authority: This investigation is being
conducted under the authority of section 421
of the Trade Act of 1974; this notice is
published pursuant to section 206.3 of the
Commission’s rules.
VerDate Nov<24>2008
17:48 Apr 28, 2009
Jkt 217001
By order of the Commission.
Marilyn R. Abbott,
Secretary to the Commission.
Issued: April 24, 2009.
William R. Bishop,
Acting Secretary to the Commission.
[FR Doc. E9–9760 Filed 4–28–09; 8:45 am]
a registration under this Section to a
bulk manufacturer of a controlled
substance in schedule I or II, and prior
to issuing a regulation under 21 U.S.C.
952(a)(2) authorizing the importation of
such a substance, provide
manufacturers holding registrations for
the bulk manufacture of the substance
BILLING CODE P
an opportunity for a hearing.
Therefore, in accordance with Title 21
DEPARTMENT OF JUSTICE
Code of Federal Regulations
§ 1301.34(a), this is notice that on
Drug Enforcement Administration
February 20, 2009, Meridian Medical
Technologies, 2555 Hermelin Drive, St.
Importer of Controlled Substances;
Louis, Missouri 63144, made
Notice of Application
application by renewal to the Drug
This is notice that on March 10, 2009, Enforcement Administration (DEA) to
Penick Corporation, 33 Industrial Park
be registered as an importer of
Road, Pennsville, New Jersey 08070,
Morphine (9300), a basic class of
made application by renewal to the
controlled substance listed in schedule
Drug Enforcement Administration
II.
(DEA) for registration as an importer of
The company plans to import
the basic classes of controlled
products for research experimentation
substances listed in schedule II.
or clinical use and analytical testing.
Drug
Schedule
Any bulk manufacturer who is
presently, or is applying to be,
Coca Leaves (9040) .....................
II
Raw Opium (9600) .......................
II registered with DEA to manufacture
Poppy Straw (9650) ......................
II such basic class of controlled substance
may file comments or objections to the
Concentrate of Poppy Straw
(9670) ........................................
II issuance of the proposed registration
and may, at the same time, file a written
The company plans to import the
request for a hearing on such
listed controlled substances to
application pursuant to 21 CFR 1301.43
manufacture bulk controlled substance
and in such form as prescribed by 21
intermediates for sale to its customers.
CFR 1316.47.
As noted in a previous notice
Any such comments or objections
published in the Federal Register on
being sent via regular mail should be
September 23, 1975 (40 FR 43745), all
addressed, in quintuplicate, to the Drug
applicants for registration to import a
Enforcement Administration, Office of
basic class of any controlled substances
in schedule I or II are, and will continue Diversion Control, Federal Register
to be, required to demonstrate to the
Representative (ODL), 8701 Morrissette
Deputy Assistant Administrator, Office
Drive, Springfield, Virginia 22152; and
of Diversion Control, Drug Enforcement must be filed no later than May 29,
Administration, that the requirements
2009.
for such registration pursuant to 21
This procedure is to be conducted
U.S.C. 958(a); 21 U.S.C. 823(a); and 21
simultaneously with, and independent
CFR 1301.34(b), (c), (d), (e), and (f) are
of, the procedures described in 21 CFR
satisfied.
1301.34(b), (c), (d), (e), and (f). As noted
Dated: April 17, 2009.
in a previous notice published in the
Joseph T. Rannazzisi,
Federal Register on September 23, 1975
Deputy Assistant Administrator, Office of
(40 FR 43745–46), all applicants for
Diversion Control, Drug Enforcement
registration to import a basic class of
Administration.
any controlled substance listed in
[FR Doc. E9–9778 Filed 4–28–09; 8:45 am]
schedule I or II are, and will continue
BILLING CODE 4410–09–P
to be, required to demonstrate to the
Deputy Assistant Administrator, Office
of Diversion Control, Drug Enforcement
DEPARTMENT OF JUSTICE
Administration, that the requirements
for such registration pursuant to 21
Drug Enforcement Administration
U.S.C. 958(a), 21 USC § 823(a), and 21
Importer of Controlled Substances;
CFR 1301.34(b), (c), (d), (e), and (f) are
Notice of Application
satisfied.
Pursuant to 21 U.S.C. 958(i), the
Attorney General shall, prior to issuing
PO 00000
Frm 00110
Fmt 4703
Sfmt 4703
E:\FR\FM\29APN1.SGM
29APN1
Federal Register / Vol. 74, No. 81 / Wednesday, April 29, 2009 / Notices
Dated: April 17, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E9–9782 Filed 4–28–09; 8:45 am]
1301.34(b), (c), (d), (e), and (f). As noted
in a previous notice published in the
Federal Register on September 23, 1975
(40 FR 43745–46), all applicants for
registration to import the basic class of
any controlled substance in schedule I
or II are, and will continue to be,
required to demonstrate to the Deputy
Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a); 21 U.S.C. 823(a); and 21
CFR 1301.34(b), (c), (d), (e), and (f) are
satisfied.
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Application
Pursuant to 21 U.S.C. 958(i), the
Attorney General shall, prior to issuing
a registration under this section to a
bulk manufacturer of a controlled
substance in schedule I or II, and prior
to issuing a regulation under 21 U.S.C.
952(a)(2), authorizing the importation of
such a substance, provide
manufacturers holding registrations for
the bulk manufacture of the substance
an opportunity for a hearing.
Therefore, in accordance with Title 21
Code of Federal Regulations
§ 1301.34(a), this is notice that on March
10, 2009, Almac Clinical Services Inc.
(ACSI), 2661 Audubon Road, Audubon,
Pennsylvania 19403, has made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as an importer of the basic
classes of controlled substances listed in
schedule II:
Drug
pwalker on PROD1PC71 with NOTICES
Oxycodone (9143) ........................
Fentanyl (9801) ............................
17:48 Apr 28, 2009
BILLING CODE 4410–09–P
Jkt 217001
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 952(a)
and 958(a), and in accordance with 21
CFR 1301.34, the above named company
is granted registration as an importer of
the basic classes of controlled
substances listed.
Dated: April 17, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E9–9789 Filed 4–28–09; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Registration
By Notice dated January 30, 2009, and
published in the Federal Register on
February 6, 2009 (74 FR 6309),
Mallinckrodt Inc., 3600 North Second
Street, St. Louis, Missouri 63147, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as an importer of the basic
Schedule
classes of controlled substances listed in
II schedule II:
II
The company plans to import small
quantities of the listed controlled
substances in dosage form to conduct
clinical trials.
Any bulk manufacturer who is
presently, or is applying to be,
registered with DEA to manufacture
such basic classes of controlled
substances may file comments or
objections to the issuance of the
proposed registration and may, at the
same time, file a written request for a
hearing on such application pursuant to
21 CFR 1301.43, and in such form as
prescribed by 21 CFR 1316.47.
Any such comments or objections
should be addressed, in quintuplicate,
to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than May 29, 2009.
This procedure is to be conducted
simultaneously with, and independent
of, the procedures described in 21 CFR
VerDate Nov<24>2008
Dated: April 17, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E9–9780 Filed 4–28–09; 8:45 am]
19595
Drug
Schedule
Phenylacetone (8501) ..................
Coca Leaves (9040) .....................
Opium, raw (9600) .......................
Poppy Straw (9650) .....................
Poppy Straw Concentrate (9670)
II
II
II
II
II
The company plans to import the
listed controlled substances for the
manufacture of controlled substances in
bulk for distribution to its customers.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and 952(a)
and determined that the registration of
Mallinckrodt Inc. to import the basic
classes of controlled substances is
consistent with the public interest, and
with United States obligations under
international treaties, conventions, or
protocols in effect on May 1, 1971, at
this time. DEA has investigated
Mallinckrodt Inc. to ensure that the
company’s registration is consistent
with the public interest. The
investigation has included inspection
and testing of the company’s physical
PO 00000
Frm 00111
Fmt 4703
Sfmt 4703
By Notice dated December 22, 2008,
and published in the Federal Register on
December 31, 2008 (73 FR 80431), Norac
Inc., 405 S. Motor Avenue, P.O. Box
577, Azusa, California 91702–3232,
made application by renewal to the
Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of Tetrahydrocannabinols
(7370), a basic class of controlled
substance listed in schedule I.
The company plans to manufacture
the listed controlled substance in bulk
for formulation into the pharmaceutical
controlled substance Marinol® for sale
to its customers.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Norac Inc. to manufacture the listed
basic class of controlled substance is
consistent with the public interest at
this time. DEA has investigated Norac
Inc. to ensure that the company’s
registration is consistent with the public
interest. The investigation has included
inspection and testing of the company’s
physical security systems, verification
of the company’s compliance with state
and local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic class of controlled substance
listed.
E:\FR\FM\29APN1.SGM
29APN1
]]>Agencies
[Federal Register Volume 74, Number 81 (Wednesday, April 29, 2009)]
[Notices]
[Pages 19594-19595]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-9782]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances; Notice of Application
Pursuant to 21 U.S.C. 958(i), the Attorney General shall, prior to
issuing a registration under this Section to a bulk manufacturer of a
controlled substance in schedule I or II, and prior to issuing a
regulation under 21 U.S.C. 952(a)(2) authorizing the importation of
such a substance, provide manufacturers holding registrations for the
bulk manufacture of the substance an opportunity for a hearing.
Therefore, in accordance with Title 21 Code of Federal Regulations
Sec. 1301.34(a), this is notice that on February 20, 2009, Meridian
Medical Technologies, 2555 Hermelin Drive, St. Louis, Missouri 63144,
made application by renewal to the Drug Enforcement Administration
(DEA) to be registered as an importer of Morphine (9300), a basic class
of controlled substance listed in schedule II.
The company plans to import products for research experimentation
or clinical use and analytical testing.
Any bulk manufacturer who is presently, or is applying to be,
registered with DEA to manufacture such basic class of controlled
substance may file comments or objections to the issuance of the
proposed registration and may, at the same time, file a written request
for a hearing on such application pursuant to 21 CFR 1301.43 and in
such form as prescribed by 21 CFR 1316.47.
Any such comments or objections being sent via regular mail should
be addressed, in quintuplicate, to the Drug Enforcement Administration,
Office of Diversion Control, Federal Register Representative (ODL),
8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed
no later than May 29, 2009.
This procedure is to be conducted simultaneously with, and
independent of, the procedures described in 21 CFR 1301.34(b), (c),
(d), (e), and (f). As noted in a previous notice published in the
Federal Register on September 23, 1975 (40 FR 43745-46), all applicants
for registration to import a basic class of any controlled substance
listed in schedule I or II are, and will continue to be, required to
demonstrate to the Deputy Assistant Administrator, Office of Diversion
Control, Drug Enforcement Administration, that the requirements for
such registration pursuant to 21 U.S.C. 958(a), 21 USC Sec. 823(a),
and 21 CFR 1301.34(b), (c), (d), (e), and (f) are satisfied.
[[Page 19595]]
Dated: April 17, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. E9-9782 Filed 4-28-09; 8:45 am]
BILLING CODE 4410-09-P
